处于临床试验阶段的抗肝纤维化药物研究进展  

Progress of anti-hepatic fibrosis medicines in clinical trials

作　　者：牛伟萍 何红伟[1] 王菊仙[1] 王玉成[1] NIU Wei-ping;HE Hong-wei;WANG Ju-xian;WANG Yu-cheng(Institute of Medical Biotechnology,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100050,China)

机构地区：[1]中国医学科学院北京协和医学院医药生物技术研究所,北京100050

出　　处：《中国新药杂志》2023年第5期492-500,共9页Chinese Journal of New Drugs

基　　金：中国医学科学院医学科学创新基金资助项目(2021-I2M-1-030);中央高校基本科研业务费专项资金资助项目(3332021048)。

摘　　要：肝纤维化是继发于各种致病因素引起的肝脏损伤和炎症后组织修复过程中的代偿反应,研究发现,肝纤维化是一种可逆性病变,如果能在此阶段给予有效的治疗,将对慢性肝炎的治疗、肝硬化和肝癌的预防具有重要意义。目前被批准用于治疗肝纤维化的药物较少,很多药物还处在临床试验阶段。处于临床试验阶段的抗肝纤维化药物有CC趋化因子受体2/5拮抗剂、法尼醇X受体激动剂、细胞凋亡信号调节激酶(ASK1)抑制剂等,本文将对处于临床试验阶段的抗肝纤维化药物的作用机制和研究进展进行总结。Hepatic fibrosis is a pathological consequence of the development of chronic liver disease.Previous research found that hepatic fibrosis is a reversible disease.If effective treatment can be given to hepatic fibrosis stage,it will be of great significance for the treatment of chronic hepatitis,the prevention of cirrhosis and liver cancer.There are limited medicines approved for the treatment of hepatic fibrosis,most of which are still in clinical trials.Anti-hepatic fibrosis medicines that are in clinical trial stage include CC chemokine receptor 2/5 antagonist,farnesoid X receptor agonist,ASK1 inhibitor,etc.This article mainly introduces the mechanism and research progress of anti-hepatic fibrosis medicines in clinical trial.

关 键 词：抗肝纤维化 可逆性病变 临床试验 

分 类 号：R961[医药卫生—药理学]